About our Carrier Screening

Fragile X Dx

Fragile X syndrome (FXS) is the most common inherited form of intellectual disability and autism, affecting approximately 1 in 4,000 males and 1 in 8,000 females in the United States.1 The disorder is X-linked and is caused by a full mutation expansion (>200 CGG repeats) within the FMR1 gene. Testing for fragile X syndrome and its associated disorders (FXTAS, FXPOI) necessitates the accurate sizing of FMR1 CGG repeats across distinct clinical categories: normal (5-44 repeats), intermediate (45-54 repeats), and premutation (55-200 repeats).

The AmplideX® Fragile X Dx & Carrier Screen Kit is an in vitro diagnostic device intended for carrier testing in adults of reproductive age. Based on Asuragen’s unique, PCR-only approach, the assay reliably amplifies and detects all alleles, including low-level mosaics and full mutations.

Read Brochure

Learn more >

 

SMN

Copy number variations in SMN1 and SMN2 are, respectively, associated with the onset and severity of spinal muscular atrophy (SMA), a debilitating and life-threatening illness of the central nervous system. Carrier screening for SMN 1 and 2 uses the AmplideX® PCR/CE SMN1/2 Plus Kit, which is an in vitro nucleic acid amplification kit for determination of exon 7 copy number and the genotype status of relevant variants in the SMN1 and SMN2 genes. The kit is also designed to detect certain SMN1-to-SMN2 and SMN2-to-SMN1 gene conversions by comparing sequence identity of exon 7 and intron 7. Lastly, two disease modifiers that identify Silent Carrier can be detected (see publication below).

Read Brochure

Learn more >

Publication

 

CFTR

For CFTR carrier screening, we use the AmplideX® PCR/CE CFTR Kit* to bring the simplicity and scalability of AmplideX technology to CFTR variant detection. Offering the streamlined detection of 67 pathogenic variants, covering approximately 93%† of the US population, the assay provides the broadest coverage of any commercially available, targeted testing kit. The assay Can deliver genotype results from DNA in just under five hours.

Read Brochure

Learn more>